FDA-Drug2021-08-18Class II
Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01
Eli Lilly & Company
Hazard
cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
Sold states
OH, MS, IN
Affected count
36,540 vials
Manufactured in
839 S Delaware St, N/A, Indianapolis, IN, United States
Products
Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0720-2021Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief